Page 2 - Bowel Project News Today

Lynparza reduced risk of death by 32% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer. First PARP inhibitor to...

Press release content from Business Wire. The AP news staff was not involved in its creation.

First PARP inhibitor to demonstrate overall survival benefit in early breast cancer ... | March 16, 2022

Based on the results of their new study, City of Hope researchers advised doctors against overreliance on Natera's Signatera assays for recurrence monitoring.

Based on the results of their new study, City of Hope researchers advised doctors against overreliance on Natera's Signatera assays for recurrence monitoring.

email article Patients with ultralow-risk breast cancer according to genomic assessment had excellent long-term outcomes regardless of clinical risk or whether they received adjuvant therapy, a new analysis of a randomized trial showed. The 8-year breast cancer-specific survival (BCSS) was 99.2% among patients classified as clinically high-risk but ultralow-risk by the MammaPrint 70-gene assay. Patients with an ultralow-risk genomic assessment and low clinical risk had an 8-year BCSS of 9...

Memorial Health announces new affiliation Submitted story A new Cancer Center on Memorial’s main campus will improve and enhance the patient experience with communal and private treatment areas featuring natural light and outdoor views. Submitted photo MARYSVILLE – Memorial Health is continuing its focus and dedication to the fight against cancer, with a mission to bring advanced oncology and hematology services to area residents. Two recent developments in this mission include a formal a...

December 10, 2020 Postmenopausal women may be able to skip some treatments, thereby avoiding some debilitating side effects, new research says.  Roy James Shakespeare/Getty Images It may be possible for some postmenopausal women to avoid some breast cancer treatment without compromising survival, according to two new studies presented at the San Antonio Breast Cancer Symposium (SABCS), hosted by UT Health San Antonio, the American Association for Cancer Research, and the Dan L. Duncan Comprehe...

Extended follow-up data from the phase III monarchE trial showed that adding the cyclin-dependent kinase (CDK) inhibitor abemaciclib (Verzenio) to standard adjuvant endocrine therapy continued to improve invasive disease-free survival (IDFS) among patients with high-risk, node-positive, early-stage, HR-positive, HER2-negative breast cancer, according to data presented at the 2020 San Antonio Breast Cancer Symposium, held Dec. 8-11.